Recent Finacing
Recent Raise
Blueprint Medicines develops selective kinase inhibitors using a genomics-driven discovery platform and proprietary kinase inhibitor library, advancing programs against KIT D816V-mutant cancers and FGFR4-driven hepatocellular carcinoma.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors